Missed Opportunities: Why Small Biotech Needs To Plan Ahead For Global Reach
Executive Summary
If small biotech does more to plan ahead for ex-US market requirements, companies and their investors – and crucially patients – will benefit.
You may also be interested in...
Medicare, Alzheimer’s Drugs And The Single Payer Effect
US biopharma stakeholders are getting a taste of how a single payer health care system can shape the fate of a new treatment with Medicare’s national coverage determination for amyloid-directed Alzheimer’s drugs including Biogen/Eisai’s Aduhelm.
Bluebird Bio Decision in Europe Is A Wake-Up Call For Payers and Industry
Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.
UK Parliamentarians Call For A New, Internationally Competitive Pricing System
Much-needed investment could be lost if the “uncompetitive” sales rebate rate is not reduced as part of talks on a new UK drug pricing scheme, some parliamentarians are warning.